Talphera (NASDAQ:TLPH) Trading Down 3.1% - Here's Why

Key Points

• Talphera, Inc. (NASDAQ:TLPH) experienced a 3.1% decline in trading, dropping to a low of $1.20 and closing at $1.23 with trading volume down by 28% compared to average sessions.
• Weiss Ratings has reissued a "sell (d-)" rating for Talphera, despite mixed analyst ratings with two strong buy, two buy, and one sell ratings, and an average target price of $5.00.
• The company reported earnings of ($0.10) per share, exceeding expectations of ($0.12), while analysts anticipate a current fiscal year EPS of -0.64.

Talphera, Inc. (NASDAQ:TLPH - Get Free Report) traded down 3.1% during mid-day trading on Friday . The company traded as low as $1.20 and last traded at $1.23. 358,492 shares were traded during trading, a decline of 28% from the average session volume of 499,397 shares. The stock had previously closed at $1.27.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of Talphera in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $5.00.

Talphera Stock Performance

The business has a 50-day simple moving average of $0.73 and a two-hundred day simple moving average of $0.57. The stock has a market cap of $56.08 million, a price-to-earnings ratio of -3.07 and a beta of 0.03.

Talphera (NASDAQ:TLPH - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. On average, analysts expect that Talphera, Inc. will post -0.64 earnings per share for the current fiscal year.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.